Yadav A V, Shete A S, Dabke A P, Kulkarni P V, Sakhare S S
Krishna Institute of Medical Scinces University and Institute of Pharmacy, Karad-415 110, India.
Indian J Pharm Sci. 2009 Jul;71(4):359-70. doi: 10.4103/0250-474X.57283.
Crystal form can be crucial to the performance of a dosage form. This is especially true for compounds that have intrinsic barriers to drug delivery, such as low aqueous solubility, slow dissolution in gastrointestinal media, low permeability and first-pass metabolism. The nature of the physical form and formulation tends to exhibit the greatest effect on bioavailability parameters of water insoluble compounds that need to be given orally in high doses. An alternative approach available for the enhancement of drug solubility, dissolution and bioavailability is through the application of crystal engineering of co-crystals. The physicochemical properties of the active pharmaceutical ingredients and the bulk material properties can be modified, whilst maintaining the intrinsic activity of the drug molecule. This article covers the advantages of co-crystals over salts, solvates (hydrates), solid dispersions and polymorphs, mechanism of formation of co-crystals, methods of preparation of co-crystals and application of co-crystals to modify physicochemical characteristics of active pharmaceutical ingredients along with the case studies. The intellectual property implications of creating co-crystals are also highly relevant.
晶型对剂型的性能可能至关重要。对于那些存在药物递送内在障碍的化合物来说尤其如此,比如低水溶性、在胃肠道介质中溶解缓慢、低渗透性以及首过代谢。物理形态和制剂的性质往往对需要高剂量口服的水不溶性化合物的生物利用度参数影响最大。一种可用于提高药物溶解度、溶出度和生物利用度的替代方法是通过共晶体的晶体工程应用。活性药物成分的物理化学性质和原料药性质可以得到改变,同时保持药物分子的内在活性。本文涵盖了共晶体相对于盐、溶剂化物(水合物)、固体分散体和多晶型物的优势、共晶体的形成机制、共晶体的制备方法以及共晶体在改变活性药物成分物理化学特性方面的应用,并伴有案例研究。创造共晶体的知识产权问题也高度相关。